ストックスクリーナーアプリを入手
1.07
0.93%
-0.01
アフターアワーズ：
1.04
-0.03
-2.80%
前日終値:
$1.08
開ける：
$1.08
24時間の取引高:
38,950
Relative Volume:
0.15
時価総額：
$14.10M
収益：
$743.00K
当期純損益:
$-7.63M
株価収益率:
-0.3567
EPS:
-3
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.28%
1か月 パフォーマンス:
-1.83%
6か月 パフォーマンス:
-32.28%
1年 パフォーマンス:
-70.52%
1日の値動き範囲:
$1.05
$1.09
1週間の範囲:
$1.05
$1.12
52週間の値動き範囲:
$0.98
$4.69
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
名前
Can-Fite Biopharma Ltd ADR
セクター
電話
972 3 924 1114
住所
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
CANF を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.07 | 14.10M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-10-19 | 再開されました | ROTH Capital | Buy |
| 2016-08-29 | 再開されました | Rodman & Renshaw | Buy |
| 2015-11-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース
Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
USC Law Launches New Online Certificate in Dispute Resolution - Business Wire
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
letgo Raises $100 Million in Series A Funding from Naspers - Business Wire
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
Can-Fite Biopharma Ltd ADR (CANF) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):